Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Anti-osteoporotic and Anti-menopausal Disorder Agent_Biosolomon Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Composition for preventing bone loss comprising salvia miltiorrhiza extracts and chitosan...
Email me a copy of this message

The core technology of Biosolomon Inc. is to provide promising anti-osteoporosis agents, Salvia miltiorrhiza extracts and chitosan.  The compositions comprising Salvia miltiorrhiza extracts and chitosan exhibit anti-osteoporosis activities which confirmed by tests with rat ovariectomy model(OVX).  Salvia miltiorrhiza extracts comprise Tanshinone I, tanshinone IIA, cryptotanshinone and dihydrotanshinone as effective compound. 

Background and unmet needs

Osteoporosis is one of the menopausal disorder caused by decrease in estrogen level. Aging, unbalanced dietary habits, liver diseases, thyroid diseases are also known as direct or indirect cause of osteoporosis. ERT(estrogen replacement therapy), Bisphosphonate and PTH(parathyroid hormone) had been used to treat osteoporosis but have finally failed to effectively treat osteoporosis without side effect such as headache, edema, endometrial cancer, breast cancer.  Safe anti-osteoarthritis agents or materials would occupy huge market because of innumerable world wide patients  

Discovery and Achievements

Compositions of Biosolomon Inc. has been developed on the basis of findings that the Salvia miltiorrhiza and chitosan have excellent anti-osteoporosis activity. When administered with compositions of present technology, the area of trabecular bone in OVX rat is maintained as the level of that of control rats, during other OVX decrease. in addition, the thickness of trabecular bone in OVX Is also maintained and seperations of trabecular bone are decreased. 

Trabecular bone was shown to be filled between growing junction and thick area in OVX+SM rat Present inventors identified 4 effective compounds of tanshinone I, tanshinone IIA, cryptotanshinone and dihydrotanshinone in Salvia miltiorrhiza extracts using spectroscopic technics, and selected tanshinone IIA as a marker compound.


 Based on strong anti-osteoporosis activity and natural origin of compositions, it is possible to develop as   functional food for specified health use as well as conventional drug.  In case of drug application, mass   production using organic chemistry process is available owing to identification of pharmaceutically effective   compound

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE